Related Experiment Video
Updated: May 9, 2026
07:41
Quantification, Viability Assessment, and Visualization Strategies for Acinetobacter Biofilms
Published on: August 4, 2023
Prognostic differences between VAP from Acinetobacter baumanii and VAP from other microorganisms.
Marianna Di Bonito1, Simona Caiazzo, Marta Iannazzone
1Department of Anesthesia and Intensive Care, Federico II University, Napoli, Italy.
Translational Medicine @ Unisa
|August 2, 2013
Summary
This study compared outcomes for critical patients with ventilator-associated pneumonia (VAP) caused by Acinetobacter baumanii versus other microbes. No significant differences in mortality or treatment success were found between groups, suggesting similar VAP management approaches may apply.
Area of Science:
- Infectious Diseases
- Critical Care Medicine
- Microbiology
Background:
- Nosocomial pneumonia poses significant risks to hospital patient mortality and morbidity.
- Acinetobacter baumanii, a multidrug-resistant organism, frequently causes Ventilator-Associated Pneumonia (VAP).
- Colistin is often reserved as a last-resort treatment for Acinetobacter baumanii infections.
Purpose of the Study:
- To compare clinical outcomes of VAP caused by Acinetobacter baumanii against VAP from other microorganisms in critically ill patients.
- To evaluate differences in comorbidity, prognostic scores, mortality rates, and eradication frequencies between the two VAP etiological groups.
- To assess the safety profile of Colistin in the context of Acinetobacter baumanii VAP treatment.
Main Methods:
- Retrospective study design.
- Inclusion of critical patients diagnosed with VAP.
- Comparison of patient groups based on the causative microorganism (Acinetobacter baumanii vs. others).
- Analysis of clinical data including comorbidities, prognostic scores, mortality, and microbiological eradication.
Main Results:
- No statistically significant differences were observed in comorbidity burden between the Acinetobacter baumanii and other microorganism VAP groups.
- Prognostic scores, mortality rates, and frequency of microbial eradication did not significantly differ between the study groups.
- The safety of Colistin as a therapeutic agent was evaluated, though specific outcomes related to its safety were noted.
Conclusions:
- Ventilator-Associated Pneumonia caused by Acinetobacter baumanii in critical patients may have similar clinical outcomes to VAP from other pathogens.
- The findings suggest that established VAP management strategies might be applicable regardless of the causative agent, including Acinetobacter baumanii.
- Further research into Colistin's safety and efficacy in treating Acinetobacter baumanii VAP is warranted.
Related Concept Videos
01:24Automated Microbial Diagnostics
Automated diagnostic analyzers have transformed clinical microbiology by providing rapid and reliable methods for pathogen identification and antibiotic susceptibility testing. Among these systems, the Vitek 2 is widely used because it automates the traditionally labor-intensive processes of microbial identification (ID) and antibiotic susceptibility testing (AST), delivering standardized and timely results that are essential for effective patient care.Microbial Identification with ID CardsThe...
01:29Pneumonia I: Introduction
Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
01:25Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
01:14Atypical Pneumonia
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...